{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"The rates of Grades III-IV acute GVHD were measured at 2 years according to standard Glucksberg criteria, which was 10%.","groups":[{"description":"Participants will receive one of two standard myeloablative conditioning regimens for their stem cell transplant, and will receive an aGvHD prophylaxis regimen including cyclosporine, methotrexate, and abatacept.\n\nAbatacept: Participants will receive one of two standard myeloablative conditioning regimens for their stem cell transplant, and will receive an aGvHD prophylaxis regimen including cyclosporine, methotrexate, and abatacept.","id":"OG000","title":"Abatacept"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"2 years after transplant","title":"Percentage of Participants With Grades III-IV Acute GVHD at 2 Years","type":"SECONDARY","unitOfMeasure":"percentage of participants"}